Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05219838 · ClinicalTrials.gov registry record · Phase 1
Binding and Effects of Lu AG06466 in the Brain of Healthy Men
A Phase 1 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05219838 is a Phase 1 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 8 participants.
The verdict
NCT05219838, a Phase 1 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study is being done to learn about the binding of Lu AG06466 and its major breakdown product (Lu AG06988) in the brain of healthy men having received multiple doses of Lu AG06466. As the binding will result in inhibition of an enzyme in the endocannabinoid system called monoacylglycerol lipase (MAGL), the effects on this system will be evaluated both in the blood and cerebrospinal fluid and compared to the binding in the brain.
Interventions
- DRUG Lu AG06466
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-01-18 |
| Est. Completion | 2022-08-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05219838
The ClinicalTrials.gov registry entry for NCT05219838 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lu AG06466 is the first listed.
NCT05219838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05219838 about?
NCT05219838 is a clinical study titled "Binding and Effects of Lu AG06466 in the Brain of Healthy Men". This study is being done to learn about the binding of Lu AG06466 and its major breakdown product (Lu AG06988) in the brain of healthy men having received multiple doses of Lu AG06466. As the binding will result in inhibition of an enzyme in the endocannabinoid system called monoacylglycerol lipase ...
What is the current status of trial NCT05219838?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2022-01-18. Estimated completion is 2022-08-29.
What interventions are being tested in trial NCT05219838?
The interventions under investigation include: Lu AG06466 (DRUG).
Who is sponsoring clinical trial NCT05219838?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.